Stone procedure: Can XS modifier be used when only 1 CPT code is submitted?
Jonathan Rubenstein, MD, and Mark Painter tackle a question regarding billing for a stone procedure.
Treatment alternatives to radical cystectomy for bladder cancer continue to evolve
"Therapeutic strategies are needed in the management of NMIBC that recurs after gold-standard intravesical BCG," Gomella writes.
How to use data to measure adherence to clinical guidelines in prostate cancer
Against the backdrop of a new guideline for advanced prostate cancer, Robert A. Dowling, MD, describes how you might measure adherence to guidelines in your own practice.
Quality performance initiative may improve TURBT outcomes in bladder cancer
Increased usage of bladder diagrams was observed following implementation of the program.
Urology Practice: How do you bill for virtual visits lasting more than 30 minutes?
E/M guidelines direct code selection based on face-to-face time with patient.
Cancer-related pain indicative of poor prognosis for metastatic CSPC
Investigators found that while patients without pain had an overall survival of 56 months, patients with pain had an overall survival of only 27 months.
The business of urology: Reducing required minimum distributions in retirement accounts
Converting funds to Roth dollars is among the most effective strategies.
Urology malpractice consult: Patient dies following lithotripsy procedure
Stone embedded in bladder wall, causing slow bleed
Microhematuria guideline emphasizes risk-stratified approach
A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.
Wearable neuromodulation device shows promise for overactive bladder
Feasibility study results indicate the nonimplanted, intravaginal device is safe and comfortable.
How do you decide between partial and radical nephrectomy?
“It’s case dependent. For appropriately selected patients, partial nephrectomy is preferred," says one urologist.
18F-DCFPyL–PET/CT demonstrates effective diagnostic performance in biochemically recurrent prostate cancer
The phase 3 CONDOR study demonstrated excellent diagnostic performance with 18F-DCFPyL–PET/CT in men with biochemically relapsed prostate cancer, even at very low PSA values.
Risk of skeletal-related events in mCRPC not associated with race
A study found no association between Black race and risk of skeletal-related events and all-cause mortality in men with newly diagnosed, bone metastatic castration-resistant prostate cancer.
Analysis identifies genomic treatment targets in African American men with prostate cancer
Findings create opportunity to develop precision medicine options for this underserved patient population.
Panel expert details changes to AUA BPH guideline
Steven A. Kaplan, MD, explains the updates in the AUA 2020 guideline on lower urinary tract symptoms secondary to benign prostatic hyperplasia.
New super‐pulse thulium fiber laser system for urinary stones launched in US
The Soltive Laser System, which uses thulium fiber laser technology, has been shown to generate finer particulate and dusted stones in half the time as a standard holmium yttrium aluminium garnet laser.
AUA 2020: Disorders of ejaculation guidelines hailed as “most scientifically rigorous to date”
Alan W. Shindel, MD, provides an expert summary and analysis of the 2020 AUA Guidelines for Disorders of Ejaculation.
AUA 2020: Experts explain new guideline for advanced prostate cancer
William Lowrance, MD, and Michael S. Cookson, MD, highlight the core components of the new AUA Guideline for Advanced Prostate Cancer.
Consensus guideline for advanced prostate cancer released by AUA, ASTRO, and SUO
The American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology have released a joint guideline for advanced prostate cancer to address the growing treatment options and complexity of the paradigm.
AUA updates guideline for surgical management of BPH-related lower urinary tract symptoms
The guidelines are an evidence-based clinical reference for the treatment of patients with lower urinary tract symptoms secondary to BPH.
2 Clarke Drive Cranbury, NJ 08512